Hourdebaigt-Larrusse P, Perchet H
Ann Cardiol Angeiol (Paris). 1985 Nov;34(9):637-41.
The cardiovascular tolerance of mianserin, a tetracyclic antidepressant with anxiolytic properties, at a dose of 30 to 90 mg/day, is studied in 27 patients affected by acute cardiopathies and attended for two months by a cardiologist and a psychiatrist. From the cardiovascular point of view progression is as usual, with two deaths from recurrence of a massive infarct, prognosis in agreement with the literature. A clinical examination, the electrocardiogram and Holter monitoring did not reveal any side effects. Psychiatric progression is favourable, in conformity with studies of the antidepressive and anxiolytic properties of mianserin. These results are compared with those of tricyclic antidepressants usually employed up to now in similar cases, with their well-known cardiovascular risks, particularly in the case of an overdose. The authors thus suggest the use of mianserin in the acute phase of all cardiopathies, in cases of depression and/or anxiety, because it is efficacious and well-tolerated, whereas a tricyclic antidepressant would not be easy to handle, dangerous, indeed formally contra-indicated. By extension, they suggest its use in chronic cardiopathies.
对27例患有急性心脏病的患者进行了研究,这些患者每天服用30至90毫克具有抗焦虑特性的四环类抗抑郁药米安色林,由心脏病专家和精神科医生随访两个月。从心血管角度来看,病情发展如常,有两例因大面积梗死复发死亡,预后与文献一致。临床检查、心电图和动态心电图监测均未发现任何副作用。精神状态进展良好,符合米安色林抗抑郁和抗焦虑特性的研究结果。将这些结果与目前在类似病例中常用的三环类抗抑郁药的结果进行比较,三环类抗抑郁药具有众所周知的心血管风险,尤其是在过量用药的情况下。因此,作者建议在所有心脏病的急性期,对于伴有抑郁和/或焦虑的病例使用米安色林,因为它有效且耐受性良好,而三环类抗抑郁药不易使用,有危险,实际上是正式禁忌的。推广而言,他们建议在慢性心脏病中使用米安色林。